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Abstract
Pinpointing the small number of causal variants among the abundant naturally occurring genetic variation is a difficult
challenge, but a crucial one for understanding precise molecular mechanisms of disease and follow-up functional studies.
We propose and investigate two complementary statistical approaches for identification of rare causal variants in
sequencing studies: a backward elimination procedure based on groupwise association tests, and a hierarchical approach
that can integrate sequencing data with diverse functional and evolutionary conservation annotations for individual
variants. Using simulations, we show that incorporation of multiple bioinformatic predictors of deleteriousness, such as
PolyPhen-2, SIFT and GERP++ scores, can improve the power to discover truly causal variants. As proof of principle, we apply
the proposed methods to VPS13B, a gene mutated in the rare neurodevelopmental disorder called Cohen syndrome, and
recently reported with recessive variants in autism. We identify a small set of promising candidates for causal variants,
including two loss-of-function variants and a rare, homozygous probably-damaging variant that could contribute to autism
risk.
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Introduction
The tremendous progress in massively parallel sequencing (aka
‘next generation’ sequencing) technologies enables investigators to
obtain genetic information down to single base resolution on a
genome-wide scale in a rapid and cost efficient manner [1,2,3].
The resulting datasets are high dimensional and very sparse, with
millions of genetic variants, the vast majority of which are rare in
the population. For example, in any genetic region, it is expected
that over 90% of genetic variants have a frequency in the
population of less than 1% [4]. Therefore in any given study, most
variants are only observed a small number of times (e.g. many of
them are singletons or doubletons). This sparse nature of the data
poses nontrivial statistical difficulties, and traditional statistical
methods employed for association testing with common variants
are not powerful in this context [5].
Both empirical and theoretical studies suggest that rare genetic
variants are an important contributor to disease risk [6,7,8,9]. Over
the past few years several statistical tests have been proposed to test
for association with rare variants in a small genetic region, such as a
gene [10,11,12,13,14,15,16,17]. The proposed association tests are
based on the idea of grouping together variants in the gene, and
testing for association at the gene rather than variant level. While
these methods attempt to increase power by cumulating the signal
across a larger region, they compromise precision and, in particular,
it is not possible to pinpoint individual causal variants and estimate
their effects on disease. Prioritizing a small number of plausible
causal variant candidates is very important for further follow-up
functional studies, since experimental analyses are difficult to
implement and expensive for large number of variants [18,19].
Furthermore, identification of causal variants is essential for
understanding the precise molecular mechanisms of disease. Despite
its importance, this problem is only now possible to address due to
the increasing availability of large-scale sequencing data and the
advances in computational methods for predicting the functional
effects of genetic variation [19].
The fundamental challenge in pinpointing rare causal variants is
that these variants are observed very infrequently in any given
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dataset and these sparse frequencies on their own are insufficient to
provide meaningful risk predictions. In particular, for singletons or
doubletons it will be necessary to incorporate prior functional and
evolutionary conservation information in order to prioritize them as
likely causal. Hierarchical modeling offers a natural strategy to
leverage collective evidence from rare variants with sparse data.
This can be accomplished in the presence of hierarchical covariates
that are associated with disease risk and which can be used for
implicitly aggregating the rare variants to permit stronger inferences
about individual variants. These hierarchical covariates are
characteristics of the variants themselves, such as the degree of
conservation across species, the position in the gene, and other
features that can be represented using bioinformatic measures.
Indeed, many annotation tools (such as ANNOVAR [20],
PolyPhen-2 [21], SIFT [22], GERP++ [23]) exist to predict the
possible impact of a variant on the function of a human protein, or
the level of evolutionary constraint for a variant. Even though such
bioinformatic predictions of deleteriousness are not extremely
accurate and are continuously being improved, they can provide
useful information on the prior likelihood that a variant is causal,
especially when multiple such predictors are used, as we show in this
work. In earlier work we have developed a hierarchical modeling
approach that is capable of estimating odds ratios for variants that
occur infrequently in the dataset [24,25]. Hierarchical regression
techniques have also been adopted in a Bayesian framework with
the goal of detecting rare causal variants [26,27], however they can
be computationally intensive and can be dependent on the choice of
the prior weights [27]. More recently, Pickrell [28] has used
hierarchical models to combine rich functional genomics annota-
tions (as generated by the ENCODE project [29]) and summary
statistics from GWAS to identify types of genomic elements
enriched among disease susceptibility loci.
Here we propose and investigate the performance of two
complementary statistical methods that are able to incorporate
prior information on the putative function of individual variants in a
gene in order to (1) identify a list of likely causal variants, and (2)
estimate the effects of these variants on disease. The first approach is
a backward elimination procedure based on groupwise association
tests that leads to the identification of a small set of ‘‘interesting’’
variants in the gene, which are enriched in causal variants. The
second approach complements the first by employing hierarchical
models [24,25] that can incorporate diverse functional and
evolutionary conservation annotations, and in turn provides effect
size estimates and confidence intervals for individual variants.
Methods
First, we review the basics of groupwise association tests, and
then we describe in detail the two complementary methods we
propose for prioritizing variants for follow-up functional studies.
Groupwise association tests for sequencing data
We assume that n subjects have been sequenced in a region of
interest (e.g., a gene), that contains m variants. Let X be the n|m
genotype matrix. We consider the regression model
g½E(Yi)~a0zCiazXib ð1Þ
where g :ð Þ is a link function, and can be set to be the identity
function when traits are continuous, or the logistic function when
traits are dichotomous; a~(a1, . . . ,ap)’ are regression coefficients
for the covariates Ci~(Ci1, . . . ,Cip) that we want to adjust for.
Xi~(Xi1, . . . ,Xim) is the vector of genotypes for the ith individual,
and Yi is its trait value. b~(b1, . . . ,bm)’ are regression coefficients
for the m genetic variants.
We are interested in testing the null hypothesis of no genetic
effects: H0 : b~0: Testing each individual bj~0 or using
multiple df tests can lack power because of the sparsity of the
data and the many variants in a gene. Therefore, we need to
impose certain assumptions on bj ’s to make the test more
powerful. For example, one of the most widely used tests, the
Burden test, assumes that all b’s have essentially the same value,
say b0, and the regression model in (1) amounts to
g½E(Yi)~a0zCiazb0
Pm
j~1 Xij . More generally, Lee et al.
[15] assume that b is a random variable with E(bj)~0,
Var(bj)~w
2
j t and corr(bj ,bk)~r for different j and k. To test
the null hypothesis of no genetic effects H0 : b~0 the variance-
component score statistic has been proposed [15]:
Qr~(Y{ bm0)’Kr(Y{ bm0), ð2Þ
where Kr~XWRrWX’, and Rr~(1{r)Izr11’ specifies an
exchangeable correlation matrix, and W~diag(w1, . . . ,wm) is a
diagonal weight matrix, where each weight can be related, for
example, to the predicted functional effect of a variant (e.g.
PolyPhen-2 or SIFT score); for a dichotomous trait, bm0 is a vector
of estimated probabilities of Y under the null model. Although this
class of tests is more general, the two commonly used tests are the
Burden test (r~1) and the SKAT test (r~0). These score statistics



















The null distribution of Qr is approximated by a mixture of x
2
1
distributions. Davies’ method [30] or moment matching can be
Author Summary
Sequencing technologies allow identification of genetic
variants down to single base resolution for a whole human
genome. The vast majority of these variants (over 90%) are
rare, with population frequencies less than 1%. Further-
more, in a specific study, many of the variants identified
are not associated with the disease of interest, and
identification of the small proportion of truly causal
variants is a difficult task. Clearly, for causal variants that
are rare enough to only appear a few times in a study,
observed frequencies in cases and controls are not enough
to distinguish them from the vast majority of random
variation, and rich functional annotations can help identify
the causal variants. Here we propose to develop a set of
statistical methods that leverage diverse functional geno-
mics annotations with sequencing data to identify a small
set of potentially causal variants and estimate their effects.
Pinpointing a subset of potentially causal variants is crucial
for understanding precise biological mechanisms, and for
further experimental functional studies.
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employed to calculate the p value. The relative performance of the
two tests will depend on the true underlying disease model. The
Burden test tends to be more powerful when disease associated
variants are all of the same type (risk or protective) and with effects
of similar magnitude. The SKAT test tends to be more powerful
when there is a mixture of risk and protective variants, and also
when only a small percentage of variants in a region are causal. A
parallel framework for family-based designs has also been
proposed [16].
Backward elimination procedure
The groupwise association tests described above test for
association at a gene level, but are not able to pinpoint individual
causal variants in the gene. However, once a gene has been shown
to contain variants associated with disease (e.g. using the Burden
or SKAT tests), identifying the individual causal variants among
the many variants in a gene is of considerable interest as it can lead
to a better understanding of the molecular mechanisms underlying
a complex trait, and is essential for further experimental validation
work.
Starting with a groupwise association test, one natural way to
identify causal variants that are individually of weak effect is to
evaluate their contribution to a given set of variants by removing
the variant from the set, and assessing the resulting effect, e.g. the
p value for the reduced set. The following iterative algorithm
(essentially a backward elimination procedure) is designed for this
purpose.
Backward Elimination Algorithm: Step 1. Start with a set
of r variants V~fu1, . . . ,urg. The current set is Vc~V . Compute
the score statistic Qr in eq. (2) (either r~0 or r~1) for this
current set Vc, and compute the p value: pVc .
Step 2. Remove each of the r variants one at a time from Vc, i.e.
consider the sets V{i~fu1, . . . , ui{1, uiz1, . . . , urg with
i~1 . . . r, and then compute the corresponding score statistic
and p value for each of these reduced sets: pV{i .
Step 3. If min(pV{1 , . . . , pV{r )ƒpVc then remove the variant k
that leads to the smallest p value:
k~argmin(pV{1 , . . . , pV{r ):
The current set becomes Vc~V{k and repeat steps 2 & 3. If the
current p value cannot be improved, then go to step 4.
Step 4. Return the current set of variants.
The results on a typical simulated example are shown in Figure
S1. We show there the effect of removing a causal variant on the p
value of the reduced set (i.e. pV{i in Step 2 above), compared to
removing a non-causal variant. As shown, the removal of causal
variants will tend to result in an increase in the p value for the
reduced set, as desired. There is a highly significant difference in
the p values for the reduced sets when removing causal vs. non-
causal variants (bootstrap Kolmogorov-Smirnov test p value
v10{6).
This algorithm is applicable when the number of variants we
start with in Step 1 is not too large (otherwise, the contribution of a
weak variant to a large set is difficult to evaluate). However,
sequencing a gene in thousands of individuals can lead to the
detection of potentially hundreds of variants, or more. Therefore,
we use a resampling procedure, whereby each time a small
number of variants is chosen (say r~10{20) from the large
number of variants identified in a gene, and then the above
algorithm is applied to such small sets a large number of times (in
our examples we use 2000 such re-samplings, although this
number can be increased in the case of a large number of variants
in the gene). At the end, for each variant in the gene we calculate
the number of times it was returned in Step 4; we call this number
the return count for a variant. A similar resampling procedure has
been applied before in the context of gene-by-gene interaction
[31]. Our goal is to use the sample of return counts to partition
variants into two groups: ‘‘interesting’’ (higher return counts) and
‘‘non-interesting’’ (lower return counts), with the ‘‘interesting’’
category expected to be enriched in disease causing variants. We
use nonparametric EM-like methods [32] to identify the two
subgroups (see Text S2 for more details).
Integrating functional annotation into the above
algorithm. It is well recognized that certain functional catego-
ries are more likely to be enriched among causal variants than
others [28,33]. An obvious example is rare non-synonymous
variants, which are known to be enriched among disease causing
variants. Similarly, loss-of-function (LoF) variants, including
nonsense, splice-site and frameshift mutations, are heavily
enriched among causal variants [18]. Therefore stratifying
variants by different functional categories can improve false
discovery rates. We can incorporate information on functional
annotation in the backward elimination algorithm above. This can
be done by simply applying the algorithm within different classes,
say non-synonymous and synonymous. Furthermore, other
functional or conservation scores (such as PolyPhen-2, SIFT and
GERP++ scores) can be explicitly incorporated in the Burden and
SKAT score statistics themselves (as weights associated with
individual variants in eq. (2)), although only one such score can be
incorporated at a time.
Hierarchical model to estimate odds ratios of individual
rare variants
A complementary approach to the backward elimination
procedure described above is a hierarchical model. Hierarchi-
cal modeling has several important advantages in the analysis
of rare variant data, because it can naturally integrate various
functional prediction scores for individual variants. Such prior
knowledge will be essential in pinpointing the likely causal
variants in a gene, especially for causal variants that are rare
enough to only appear a few times in a study (e.g. singletons
and doubletons). For such variants, observed frequencies in
cases and controls are clearly not enough to distinguish them
from the vast majority of random variation (in the Nelson et al.
study [4], more than 74% of variants were singletons or
doubletons). Information on the putative functional effect of a
variant on the protein or the degree of evolutionary conser-
vation can be an important indicator on the likelihood of a
variant being causal.
Such functional information can be incorporated through a
hierarchical model [24,25]. In the first stage, the trait value Y is
related to the genotypes and possible confounders via the following
model:
g½E(Yi)~a0zCiazXib, ð5Þ
with notations similar to those in model (1) above.
A second stage model relates the individual variant risks to prior
(e.g. functional annotation) information known about the variants:
b~Zªzd, ð6Þ
where Z is an m|k matrix for the k variant covariates (e.g.
functional information); c is a k|1 vector of regression
Identification of Rare Causal Variants in Sequence-Based Studies
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parameters for the second stage covariates, and d is a vector of
normally distributed residual effects, assumed (for convenience) to
be statistically independent. A principal advantage of the
hierarchical modeling framework is that it can easily incorporate
multiple functional annotations.
Combining the two models, one obtains the following gener-
alized linear mixed effects model:
g½E(Yi)~a0zCiazXiZªzXid: ð7Þ
The parameters of this model can be estimated using a hybrid
Bayesian pseudo-likelihood approach which performs Bayesian
estimation of the variance component of the model and then
conducts pseudo-likelihood estimation of the fixed and random
effects using this estimated random effects variance [24,25]. We
can use the resulting estimates for the odds ratios and their
standard errors to rank variants in a gene. Naturally the most
difficult to identify are causal variants that occur only a few
times. The odds ratio estimates for such variants will heavily
depend on the higher level covariates, such as information on
the predicted functional effect for a variant. For example, for a
variant that occurs infrequently in a dataset (e.g. 2 times in cases
and 0 times in controls), knowing that it is a LoF variant
increases its likelihood to be a causal variant compared with a
synonymous variant with the same frequency.
Backward elimination procedure and hierarchical
model. We combine the two complementary methods, the
backward elimination procedure and the hierarchical modeling
framework, as follows. We identify the list of ‘‘interesting’’ variants
from the backward elimination procedure, and for each of these
variants we report the effect size estimate, and the associated
standard error obtained from the hierarchical model (when
applied to all variants, not just to the ‘‘interesting’’ list). The
variants in the ‘‘interesting’’ list can be naturally ranked according
to these effect estimates. We show below that restricting attention
to only the list of ‘‘interesting’’ variants can improve the ranking of
causal variants, and that this combined approach performs well in
the scenarios we investigated.
Both methods are computationally efficient and have been
implemented in software available on the authors’ website (http://
www.columbia.edu/,ii2135/).
Results
We evaluate the performance of the proposed methods using
simulated data and then apply them to two sequencing studies, the
Dallas Heart Study and a study on Autism Spectrum Disorders.
Simulated data
We simulated sequence data on 10,000 haplotypes in one
genomic region of length 1 Mb under a coalescent model using the
software package COSI [34]. The model used in the simulations
was the calibrated model for the European population. For our
purposes, we randomly sampled small subregions of size 10 kb,
and simulated datasets with n~2000 individuals (equal number of
cases and controls). The number of variants and the minor allele
frequency (MAF) distribution varies depending on the subregion
sampled.
We considered two disease models (Table 1). In these two
models, the odds ratio (OR) is a decreasing function of the MAF.
For both models, we assume that 10%{20% of the variants with
MAF #0.05 in the 10 kb region under investigation are causal
variants.
For a dichotomous trait, we assumed the logistic model:
logit½P(Yi~1)~a0zb1Xi1z . . .zbmXim,
with a0 chosen such that the disease prevalence was 0.05.
We have also simulated bioinformatic covariates for variants to
be used in the backward elimination algorithm, as well as to be
incorporated in the hierarchical model. A first bioinformatic
covariate we simulate is a binary variable, such as whether a
variant is non-synonymous or not. Based on empirical studies [4],
we consider the non-synonymous to synonymous ratio (NS:S) for
the rare variants in the region to be between 0:6{1:4 (depending
on the strength of the purifying selection in the region). We assume
that 80% of causal variants are non-synonymous, and then using
Bayes’ rule we calculate the proportion of non-causal variants that
are non-synonymous (see Table 2). Given these settings, the
proportions of causal variants among non-synonymous and
synonymous variants can be easily derived and are reported for
completeness in Table 2.
Furthermore, additional variant annotation tools for non-
synonymous variants exist, and are able, for example, to predict
the damaging effect of an amino acid substitution (PolyPhen-2 and
SIFT), and to assess the extent of evolutionary conservation at a
position (GERP++). Therefore, for non-synonymous variants we
simulate two additional predictors, as follows. The first bioinfor-
matic predictor (B1) for non-synonymous variants is defined as a
binary indicator whether a variant is predicted to be damaging or
not. Following the empirical results in Cooper et al. [18] we
assume that 30% of non-synonymous, non-causal variants are
damaging (possibly or probably), and that 80% of non-synony-
mous, causal variants are damaging (Table 2). A second bioinfor-
matic predictor (B2) is also defined as a binary indicator whether a
variant is predicted to be probably damaging or not. Again, as in
Cooper et al. [18] we assume that 10% of non-synonymous, non-
causal variants are probably damaging, and that 80% of non-
synonymous, causal variants are probably damaging (Table 2). To
assess the effect of using a non-informative predictor, we also
simulate a binary predictor with 50% non-synonymous causal and
50% non-synonymous non-causal variants having a value of 1 for
this non-informative predictor.
The main goal of the proposed methods is to combine
sequencing data with functional predictions about the deleteri-
ousness of variants to identify a set of promising variants, enriched
in causal variants. Furthermore, the selected variants can be
ranked according to their return counts from the backward
elimination procedure, or the estimated b^ effects from the
hierarchical model (ranking based on Z scores gave similar
results). We use several measures to assess the performance of the
methods. The main measures are: (1) the overall ranking of the
true causal variants among the variants in the gene, and (2) the
bias and coverage accuracy in the estimation of effect sizes for the
variants from the hierarchical model.
Ranking of causal variants: Simulation results
Nonparametric mixture modeling of return counts. In
what follows, we apply the backward elimination procedure
described in Methodsseparately to non-synonymous and synony-
mous variants. Since the non-synonymous variants tend to be
enriched in causal variants, the sample distribution of return counts
obtained for the non-synonymous variants tends to exhibit two
separate subgroups (a ‘‘non-interesting’’ group, enriched in null
variants, and an ‘‘interesting’’ group, enriched in causal variants).
We identify these two groups using an expectation-maximization
Identification of Rare Causal Variants in Sequence-Based Studies
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(EM) algorithm for nonparametric estimation of mixture models
and declare as ‘‘interesting’’ those variants belonging to the right tail
component (which corresponds to the larger return counts). This is
illustrated in Figure S2 which depicts for a simulated example the
histogram of return counts for non-synonymous variants with the
fitted two-component mixture overlaid.
For synonymous variants, since only a small proportion of
causal variants are expected to be synonymous, the sample
distribution of return counts often fails to exhibit separate groups
in our simulations; therefore we select the variants with the top
20% return counts as ‘‘interesting’’ to be further investigated;
although we expect less than 20% of synonymous variants to be
causal (indeed in our simulations only 3%–10% of the synonymous
variants were causal), we conservatively choose the threshold of
20% to increase the probability of selecting causal variants,
especially since for synonymous variants, unlike the non-synony-
mous ones, we do not make use of additional information in
prioritizing variants.
Ranking of causal variants Non-synonymous vs.
synonymous
We employ the backward elimination procedure as well as fit a
hierarchical model including the full set of variants and assuming a
single functional predictor in the second stage, namely whether a
variant is non-synonymous or synonymous. Due to the expected
difference in enrichment of causal variants among non-synony-
mous versus synonymous variants we evaluate the overall ranking
of the causal variants separately among non-synonymous and
synonymous variants. More explicitly, among the non-synony-
mous variants selected as ‘‘interesting’’ by the backward elimina-
tion procedure we rank the causal variants based on their return
counts (this approach is denoted as BE in the figures below).
Furthermore, we also use the b^ estimates obtained from the
hierarchical model to rank the causal variants among all non-
synonymous variants (HM) as well as among the non-synonymous
variants selected as ‘‘interesting’’ by the backward elimination
procedure (HMS). For each simulation we take the median of the
ranks of the causal variants involved and then compute the median
of these estimates across simulations. The ranking for the
synonymous variants is done similarly.
Figures 1(a) and S3(a) present the median ranks of the causal
non-synonymous variants based on the different ranking proce-
dures (HM, BE, and HMS). The hierarchical model (titled ‘‘HM’’
in the figure) results in higher median rank (worse performance)
than that of the backward elimination procedure (titled ‘‘BE’’ in
the figure). This is of course expected due to the smaller number of
variants that the backward elimination procedure returns as
‘‘interesting’’ (Figures 1(a) and S3(a)). However, despite excluding
a substantial proportion of variants in the backward elimination
process (the ‘‘non-interesting’’ category), we show that the top
ranked causal variants in the hierarchical model are kept in the
selected list (Figures 1(b) and S3(b)). For the scenarios investigated,
the number of causal, non-synonymous variants in the top 10
ranked variants varies between 5 and 8 for the case when the
percentage of causal variants in a region is 20% (Figure 1(b)), and
3–6 for the case with only 10% causal variants (Figure S3(b)).
When looking only among the ‘‘interesting’’ variants from the
backward elimination procedure, the overall ranking of causal
variants based on the hierarchical model estimates b^ (titled
‘‘HMS’’) is similar to the one based on return counts in the
Table 1. Two disease models M1 and M2.
Model Description
M1 10%{20% of variants with MAFƒ0:05 have OR~e0:2D( log10 (MAF))D
M2 10%{20% of variants with MAFƒ0:05 have OR~e0:4D( log10 (MAF))D
The odds ratio (OR) is a decreasing function of the minor allele frequency (MAF) at the causal variants.
doi:10.1371/journal.pgen.1004729.t001
Table 2. Simulation scenarios.
All Non-synonymous
B1 B2
NS:S pC pCDNS pCDS pNSDC pNSDNC pDamagingDC pDamagingDNC pProbablyDC pProbablyDNC
0.6 0.1 0.21 0.03 0.8 0.33 0.8 0.3 0.8 0.1
1.0 0.1 0.16 0.04 0.8 0.47 0.8 0.3 0.8 0.1
1.4 0.1 0.14 0.05 0.8 0.56 0.8 0.3 0.8 0.1
0.6 0.2 0.42 0.06 0.8 0.27 0.8 0.3 0.8 0.1
1.0 0.2 0.32 0.08 0.8 0.42 0.8 0.3 0.8 0.1
1.4 0.2 0.28 0.10 0.8 0.53 0.8 0.3 0.8 0.1
NS:S is the ratio of non-synonymous to synonymous variants; pC is the percentage of causal variants among the rare variants in a region, with pCDNS being the
percentage of causal variants among the non-synonymous ones, and pCDS being the proportion of causal variants among the synonymous ones; pNSDC is the proportion
of non-synonymous variants among the causal ones; pNSDNC is the proportion of non-synonymous variants among the non-causal ones (these values are calculated
based on the NS:S ratio, pC , pNSDC). For non-synonymous variants only, we simulate two additional bioinformatic predictors (B1 and B2), meant to resemble the
‘damaging’ (including possibly and probably) and ‘probably damaging’ annotations from PolyPhen-2. pDamagingDC is the proportion of causal variants that are labeled as
‘damaging’ and pDamagingDNC is the proportion of non-causal variants that are labeled as ‘damaging’. Similar notations for ‘probably damaging.’
doi:10.1371/journal.pgen.1004729.t002
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backward elimination procedure (Figures 1 and S3). Therefore the
backward elimination method can be used as an effective tool to
select and rank a set of promising variants, and reduce the overall
list of variants to a smaller, more manageable list, followed by
further characterization of these variants’ effects within the
framework of the hierarchical model. For all methods, and
regardless of disease model, the performance tends to decrease as
the non-synonymous to synonymous ratio increases from 0.6 to 1.4
(as the effect of purifying selection becomes weaker).
When looking at the synonymous variants separately, the results
are qualitatively similar to the non-synonymous case. However,
because only 20% of the causal variants are assumed synonymous,
the overall ranking of the few causal variants among the
synonymous variants is noticeably worse compared with non-
synonymous variants, as expected (Figures S4 and S5). For
example, in a region with 20% causal variants, overall we detect
between 2 and 3 causal synonymous variants among the top 10
ranked variants, and only 1–2 in a region with 10% causal
variants. Due to these high false-discovery rates for synonymous
variants, it may be more effective to focus initial efforts for causal
variant identification among the functional (non-synonymous and
LoF) variants. As genomic annotations become richer for
synonymous variants, we expect the discovery of causal variants
among synonymous variants to become more accurate.
Multiple bioinformatic predictors for non-synonymous
variants
We evaluate the effect on ranking the causal variants among
non-synonymous variants when additional bioinformatic predic-
tors are added to the hierarchical model (in addition to the
indicator whether the variant is non-synonymous vs. synonymous).
Note that synonymous variants were assigned a bioinformatic
predictor of 0.
We restrict attention to ranking only among the ‘‘interesting’’
variants, as selected by the backward elimination procedure. As
shown in Figure 2, when we add one bioinformatic predictor (B1
or B2; see Table 2), the ranking of causal variants improves
significantly compared to the original hierarchical model that only
uses a binary predictor (whether a variant is non-synonymous or
not). The improvement is more pronounced with predictor B2, due
to the higher specificity of this predictor. For example, for model
M1, a non-synonymous to synonymous ratio of 1.4 and 20%
causal variants in a region, the median number of causal variants
among the top 10 ranked non-synonymous variants increases from
5 (in the original hierarchical model) to 8 when using bioinfor-
matic predictor B2. Since we do not always know which of several
available bioinformatic predictors may have higher accuracy, the
hierarchical model allows us to combine multiple bioinformatic
predictors. When combining three bioinformatic predictors (two
predictors with the same sensitivity and specificity as B1 and one
predictor B2, all independent), we find that the ranking of causal
variants is now similar or superior to the ranking obtained when
using only the better of the two bioinformatic predictors (i.e. B2).
Similarly, when using a combination of four bioinformatic
predictors (four predictors with the same sensitivity and specificity
as B1), the ranking of causal variants is better than using just a
single predictor B1, and similar to using the more accurate
predictor B2. These results suggest that using multiple bioinfor-
matic predictors with different accuracies (even multiple weak
predictors) can help detection of the causal variants. Similar results
are obtained when the proportion of causal variants in a region is
10% (Figure S6).
We have also evaluated the effect of including a non-informative
predictor in the analysis, although in practice we expect that
functional annotations are correlated with the causal status of a
variant. The results are reported in Figures S11 and S12. As
shown, including a random (non-informative) bioinformatic
predictor does lead to worse performance compared to when
such a predictor is not included, although combining an
informative predictor (B1) together with a non-informative one
does help improve the performance. Again, the ability of the
hierarchical model to incorporate multiple functional predictors of
varying accuracy is an important feature when the best predictors
are not known a priori.
It is possible to incorporate one bioinformatic predictor, such as
B1 or B2, in the backward elimination procedure directly (as a
weight in the Burden test statistic). We found that for the case of
only one bioinformatic predictor, the backward elimination
procedure performed similarly with (or slightly worse than) the
hierarchical model (Figures S7). However, in general, it is not clear
how to choose one single functional annotation from several
annotations available. Therefore, the hierarchical model has the
important advantage that multiple bioinformatic predictors can be
included, and, as shown above, the ranking of the causal variants
improves with the addition of several predictors of varying
accuracy.
Effect size estimation for variants in the
hierarchical model
As already mentioned, the hierarchical model has distinct
advantages when multiple functional predictions are available for
variants. In particular, it is possible to provide effect size estimates
and standard errors for individual variants, that take into account
such diverse functional predictions. As seen in Table S1, for
disease model M1 (Table 1), absolute biases of the log odds ratio
estimates from the hierarchical modeling approach are similar
among the different scenarios while coverages are close to the
nominal level of 95%. In comparison, bias is further increased and
coverages are under the nominal level of 95% for disease model
M2 (which assumes higher odds ratios than model M1, Table 1),
though there is a trend towards reduced bias and improved
coverage with the addition of stronger bioinformatic predictor(s).
The biases observed here are due to several causes. One main
source of bias is the shrinkage phenomenon that occurs with
hierarchical models: in this setting of sparse data the model relies
heavily on the higher level covariates and as a result the estimated
risks of the non-causal variants with high bioinformatic predictor
scores will be biased upwards, while the risks of the causal variants
with low bioinformatic predictor values will be shrunk down,
resulting in increased bias and loss of power, respectively. As the
frequency of carriers increases, the model overrides the misclas-
sifications of the higher level covariate, yielding less biased
estimates (data not shown). This shrinkage is even more
pronounced for model M2, which assumes higher odds ratios for
the causal variants (compared to M1), resulting in the poorer
performance noted with model M2. An additional source of bias
comes from our analyses being conditional on the groupwise
(gene-based) test being significant.
Application to the Dallas Heart Study and
ANGPTL4
We first show an application of the proposed methods to a well
studied re-sequencing dataset for ANGPTL4 for 3,551 individuals
of varied ethnicity from the Dallas Heart Study. Rare and low-
frequency variants in this gene have been previously associated
with low serum triglyceride levels [35]. We consider log-
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transformed triglyceride level as our phenotype, and adjust for
gender and ethnicity. As in the original study [35], we dichotomize
the phenotype by considering the individuals in the lowest quartile
as cases, and the individuals in the highest quartile as controls, for
a total of 898 individuals with variation in this gene. We identify
20 functional variants (missense, nonsense, and frameshift).
In Table 3 we report the functional variants, ranked by the
estimated effects b^ from the hierarchical model taking into account
their PolyPhen-2 and GERP_RS scores. Also reported is the
return count from the backward elimination procedure (due to the
small number of variants in this gene we do not fit the
nonparametric mixture model in this example; instead we simply
rank all variants). All the top ranked variants that appear only in
cases (i.e. the lowest quartile) have been shown by Romeo et al.
[36] to severely compromise the function of the protein. In
particular, the top ranked variant, p.Lys217Ter, is a nonsense
variant that appears only once in an affected individual, and is
assumed to interfere with protein synthesis. The second, fourth,
seventh and eighth variants have been shown using functional
studies to lead to impaired protein secretion. The fifth variant
showed reduced ability to inhibit LPL (lipoprotein lipase) activity
in vitro, while the sixth variant introduced a premature
termination codon [36]. The third variant in the list, p.Glu40Lys,
is a missense variant (classified as probably damaging by
PolyPhen-2 and as evolutionarily conserved site by GERP_RS),
with a frequency of 1.3% in this dataset, and has been shown to be
significantly associated with plasma triglyceride levels [35].
However, due to its presence even among controls (i.e. the highest
quartile), this variant was not investigated in the functional studies
in Romeo et al. [36].
We next show an application to a gene with a larger number of
functional variants, and for which not much is known on the likely
causal variants. Hence the next application is a more difficult
example for the proposed methods.
Figure 1. (a) Median rank of causal variants among the non-synonymous variants for two disease models (M1 and M2) and three
values for the NS:S ratio (R= {0.6, 1.0, 1.4}). The proportion of causal variants in the region is 20%. HM refers to the original hierarchical model
with ranking of the causal variants among the non-synonymous variants, based on their estimated effects; BE refers to the backward elimination
procedure for non-synonymous variants; and HMS refers to the ranking of causal variants only among those non-synonymous variants selected by the
backward elimination procedure, with ranks based on the estimated effects from the hierarchical model. (b) The number of causal variants in Top 10
for non-synonymous variants.
doi:10.1371/journal.pgen.1004729.g001
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Application to the Cohen syndrome and VPS13B
The Vacuolar Protein Sorting 13 homolog B (VPS13B, also
known as COH1, MIM #607817) is a gene associated with Cohen
syndrome (CS, OMIM #216550), a rare autosomal recessive
neurodevelopmental disorder overrepresented in Finland and
common in Amish, Irish travelers and Greek/Mediterranean
founder populations [37,38]. At least 200 affected individuals of
diverse ethnic background have been reported so far with diverse
VPS13B mutations, including nonsense, missense, splicing, indels,
microdeletions and microduplications [38]. Despite clinical
heterogeneity in part related to ethnic background, the disorder
has core features, including non-progressive intellectual disability,
motor clumsiness, postnatal microcephaly, a typical facial gestalt,
hypotonia, intermittent neutropenia, and chorioretinal dystrophy
[39]. Behavioral disturbances are common among CS individuals,
and autistic traits have been reported in cases of greek/
mediterranean descent [40]. Furthermore, VPS13B mutations
have been found in individuals with autism [41] and non-
syndromic intellectual disability [42]. It is worth noting that
mutations in another member of the VPS13 gene family (VPS13A
or CHAC, MIM #605978, encoding for a protein known as
Chorein), cause chorea-acanthocytosis [43] (MIM #200150), a
recessive disorder of acanthocytosis and adult-onset choreic
involuntary movements with significant co-morbidity with psychi-
atric illness [44].
VPS13B is also an intolerant gene with a Residual Variation
Intolerance Score [45] of 22.44 (top 0.55% most intolerant genes)
in Europeans and a similar score for African Americans. We
applied the proposed methods to the 166 VPS13B variants
identified in a whole-exome sequencing autism spectrum disorders
(ASD) case/control dataset (n~860; more details on this dataset
can be found in Text S1). We tested for association with functional
(non-synonymous, nonsense and splice-sites) rare variants in this
gene and the Burden test p value was 0.01. We then used the
backward elimination algorithm to identify a set of ‘‘interesting’’
(i.e. potentially causal) variants, and for each of these variants we
report effect size estimates and standard errors from the
hierarchical model. Note that the ratio of non-synonymous to
synonymous variants in this gene is 0.84, hence towards the lower
end of values in our simulated scenarios.
Of the 166 variants in this gene, we focus on 74 that are non-
synonymous, nonsense or splice-sites (two variants affecting the
invariant splice acceptor site of the intron between exons 51 and
52 have been excluded from further analyses because they did not
validate by Sanger sequencing). Of these, the backward elimina-
Figure 2. The effect of multiple bioinformatic predictors for non-synonymous variants. Ranking is done only within the set of variants
selected by the backward elimination procedure. (a) Median rank of causal variants for two disease models (M1 and M2) and three values for the NS:S
ratio (R = {0.6, 1.0, 1.4}). The proportion of causal variants in the region is 20%. HMS refers to the hierarchical model with ranking of the causal variants
among the selected non-synonymous variants, based on their estimated effects, B1 refers to the hierarchical model with one bioinformatic predictor
(B1, Table 2), B2 refers to the hierarchical model with one bioinformatic predictor (B2), mB1 refers to the hierarchical model with three bioinformatic
predictors (B1, B1, and B2), and mB2 refers to the hierarchical model with four bioinformatic predictors (four B1s). (b) The number of causal variants in
Top 10 for non-synonymous variants.
doi:10.1371/journal.pgen.1004729.g002
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tion procedure selects 42: 2 of them are LoF (one nonsense and
one variant affecting an essential splice site), and of the missense
PolyPhen-2 predicts that 14 are probably damaging, 1 possibly
damaging, and 25 benign (Figure 3). In Figure 4(a) we show the
drop in p value each time a variant is being removed in step 3 of
the backward elimination procedure; the process stops when the p
value starts to increase as one tries to remove any of the remaining
variants. Also shown in Figure 4(b) is the distribution of return
counts (from the re-sampling procedure), and overlaid is the fitted
mixture with two distinct components. The 42 selected variants
belong to the second component of the fitted mixture (these are the
‘‘interesting’’ variants). As a comparison, applying the backward
elimination algorithm to the remaining 90 synonymous variants
results in no distinguishable ‘‘interesting’’ component (and
markedly smaller average return counts compared to the non-
synonymous case; Figure S8).
In Table 4 we report the top 20 variants among the selected
functional variants (ranked by the estimated effects b^ from the
hierarchical model), along with their PolyPhen-2 and GERP_RS
scores. Noticeably, among the top ranked variants there is a
probably damaging variant (c:9592CwT, p.Arg3198Trp, anno-
tated on NM_152564.4 and Q7Z768-2, respectively) with 5
variant copies in cases and 1 in controls, with one case being
homozygous at the position. Furthermore, the top two variants in
the list have both very high C-scores [46] (36 and 35, top 0.1%),
based on the recently introduced measure of deleteriousness
Combined Annotation-Dependent Depletion (CADD) that inte-
grates diverse genome annotations. The two LoF variants (one
nonsense (c:10148CwG, p.Ser3383Ter) and one splice site
(c:2650z2TwG)) have been seen only once in cases (i.e.
singletons). Notably, the splice variant c:2650z2TwG affects
the splice donor site of the intron between exons 18 and 19, and a
homozygous mutation in the splice acceptor site of the same intron
has been identified in an individual suffering from CS [47]. As a
first step toward the characterization of the variants, we used
Sanger sequencing to validate two cases with the c:9592CwT
variant and the cases with c:10148CwG and c:2650z2TwG
and study their inheritance pattern. This analysis is of particular
relevance for singletons, considering that the false discovery rate
among those can be high. All variants were validated and found to
be inherited (Figure S9). In one family with the c:9592CwT, both
affected children are homozygous and inherit the variant from
their parents (father homozygous and mother heterozygous -
Figure S9A). In a second family with c:9592CwT, the variant is
transmitted from heterozygous parents to one affected child, and
untransmitted to the unaffected child (Figure S9B). The
c:2650z2TwG variant is inherited from the mother (Figure
S9C), and the c:10148CwG variant is paternally transmitted to
both affected children (Figure S9D).
To understand the impact of the variants on the molecular
functions of VPS13B, all 42 variants deemed ‘‘interesting’’ by the
backward elimination procedure were projected on the protein
topology, reconstructed with the Pfam domains (N-terminal region
of Chorein, DUF1162, ATG C-terminal domain), the experimen-
tally ascertained Golgi targeting domain [47], and 11 transmem-
brane domains predicted with TMPred [48] (Figure S10). Benign
variants appear scattered along the protein topology, while some
of the predicted damaging variants map to known domains,
including a missense in the DUF1162 domain and two missense in
the Golgi targeting domain. Prediction of the structural changes
that can result from the variants using MutPred [49] further
revealed two top deleterious missense variants (p.Tyr1428His,
predicted to cause gain of disorder (p = 0.006), loss of beta-sheet
(p = 0.008) and gain of alpha-helix (p = 0.049); and p.Asp1475Gly,
predicted to cause gain of alpha-helix (p = 0.049)). The LoF
variants are upstream the Golgi domain, thus they are likely to
cause premature insertion of a stop codon, activating nonsense-
mediated mRNA decay or producing protein isoforms lacking the
Golgi targeting domain. Although the pathological mechanisms
caused by VPS13B insufficiency or mutations are still unknown,
fibroblasts isolated from individuals with CS show severe
fragmentation of the Golgi apparatus into ministacks [47], a
defect observed in neurodegenerative disorders [50] and hypoth-
esized to precede neuronal cell death [51]. Therefore, the LoF
variants might prevent proper localization of VPS13B and
disruption of its molecular functions on Golgi assembly or
maintenance, triggering the pathological cascades underlying
Cohen syndrome and/or autism.
Most of the variants selected are singletons (34 out of 42). As
previously mentioned, for singletons accurate bioinformatic
predictors about their likely functional effects are essential in
order to identify such variants as promising, and hierarchical
modeling is a natural framework to incorporate such information.
Naturally the false discovery rate among these singletons can be
high, and dependent on the sensitivity and specificity of the
bioinformatic predictors used to characterize the variants in the
hierarchical model. For comparison, in Table S2 we show the top
20 variants among the functional variants selected by the
backward elimination procedure with ranking based on return
count. No functional prediction score was used in this analysis.
Although the more common variants still occur among the top
variants in this analysis, for singletons, the hierarchical model
gives higher priority to variants with high scores for both
PolyPhen-2 and GERP_RS (Table 4). This ability of the
hierarchical model to prioritize low frequency variants by taking
into account multiple functional predictions is a distinct
advantage over ranking based on return count alone (with no
consideration of the PolyPhen-2 and GERP_RS scores for the
variants).
Discussion
Pinpointing the rare causal variants among a large number of
variants that occur in a genetic region is a difficult challenge, but
crucial for follow-up functional studies, and for a better
understanding of the molecular mechanisms that lead to disease.
For many causal variants that occur only a few times in a dataset,
incorporation of external information characterizing the variants
(such as bioinformatic predictions on the deleteriousness of a
variant) is essential to help prioritize these rare variants. We have
described here two complementary statistical methods, that are
able to integrate diverse functional annotations on individual
variants in a region, and produce a selected list of candidates for
causal variants, ranked according to their estimated effect sizes.
The backward elimination procedure offers a natural way to select
a set of promising variants, while using multiple functional
predictors in the hierarchical modeling approach provides more
in depth characterization of variants’ effects on disease, and can
help boost the power to identify causal variants. We have focused
attention here on some of the commonly used annotations for
coding regions; however we acknowledge that there are other
possible functional genomics annotations available both for the
coding and non-coding regions [28] and with continued efforts to
improve these functional predictions this list will further expand.
We illustrate the proposed methods through an application to a
gene implicated in Cohen syndrome and autism, VPS13B. For
this gene, we show that among the top selected variants are two
LoF variants, and one rare, probably damaging variant that is
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homozygous in one affected individual. Autosomal recessive
mutations associated with autism have been recognized for
decades [52]. Recently, whole-exome sequencing has provided
strong evidence that rare, recessive LoF variation is a major
contributor to risk [53]. It is likely that many recessive missense
variants contribute to ASD as well, although there has been
insufficient power in whole-exome studies carried out to date to
fully explore such variation. VPS13B is indispensable for the Golgi
apparatus, and genes important for Golgi morphology and
function have been linked to autism disorders, including RAB39B,
mutated in a X-linked intellectual disability associated with autism,
epilepsy and macrocephaly [54], and UBE3A, responsible of
Angelman syndrome [55]. In addition, disturbances in pathways
linked to Golgi, e.g. autophagy [56] and protein glycosylation [57],
have been associated with autism etiology. Our findings extend the
mutational landscape of VPS13B in Cohen syndrome and autism
and further strengthen the connection between Golgi homeostasis
and autism.
Figure 3. Predicted deleteriousness scores are shown for 71 rare functional variants (non-synonymous, nonsense and splice-sites).
From the top, the first plot depicts the PolyPhen-2 score for each variant, the second depicts the GERP_RS score, and the third depicts variant counts
for cases (up) and controls (down). Green tick marks indicate a variant contained in an exon, and red ticks indicate that a variant is selected by the
backward elimination procedure. LoF variants are marked by a black asterisk; the homozygous probably damaging variant is marked by a red asterisk.
The location of five protein domains (ChoreinN, TM2, TM4, DUF1162, Golgi targeting element, and ATG C) are depicted by boxes at the top of the plot
(see Figure S10 for a complete view of VPS13B protein domains). Variants are plotted equidistantly on the x-axis.
doi:10.1371/journal.pgen.1004729.g003
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A rather large number of selected variants in the backward
elimination procedure are singletons. Causal variants that appear
as singletons in a dataset are difficult to distinguish from random
genetic variation, and accurate functional predictions on such
variants are crucial and will help in identifying those singletons
more likely to be causal. Currently, it is not uncommon for
predictions on the deleteriousness of a variant to be discordant
(e.g. predictions from PolyPhen-2 and SIFT), and combining such
multiple predictors can be difficult, although aggregate deleteri-
ousness scores, such as Condel [58] and C-score [46], are
available. Since the hierarchical model can easily incorporate
multiple functional predictions, it has a distinct advantage over
methods that cannot consider multiple predictions at once. Indeed,
most of the existing groupwise association tests (including the
Burden and SKAT tests discussed here) can only use one
functional score at a time, and therefore it is not clear how
multiple scores (that are sometimes discordant) can be taken into
account. It is also worth noting that in the case of existing Burden
(or SKAT) tests, a variant with a low functional score (e.g.
PolyPhen-2 score close to 0) will be excluded from analysis
regardless of the evidence of association that the data suggests
(frequency in cases vs. controls). In contrast, in the presence of
sufficient case-control frequencies, the hierarchical model places
more weight on the larger case-control frequencies overriding the
information from the bioinformatic predictors when that infor-
mation does not support the likelihood of an increased risk.
Therefore, the hierarchical model has an advantage also over
simple methods to prioritize based on one functional score (e.g.
PolyPhen-2) alone.
The use of next-generation sequencing technologies may lead to
higher error rates compared to a traditional Sanger sequencing
platform. Sequencing errors may be disproportionately present
among singletons or very rare variants, especially for larger sample
sizes, although for a single gene the number of errors is expected to
be relatively small. Therefore, as a first step toward the
characterization of the top ranked variants, Sanger sequencing
can be used to validate the variants.
Classical variable selection methods (such as ridge regression
[59] and LASSO [60]) are natural tools to employ in this setting in
which the causal variants are expected to be just a small subset of
all sequenced variants. Such methods have recently been applied
to sequencing data [61,62]. However, because these methods have
not been developed to handle such sparse data, they have difficulty
in selecting very rare variants (such as singletons). Furthermore, it
is not clear how one can take into account multiple functional
predictions for variants. Further work in this area needs to be done
to assess the ability of these classical variable selection approaches
to identify rare causal variants. Other existing methods one could
use for causal variant prioritization fall into two extremes. Some
methods use only data on observed case-control frequencies. For
example, in KBAC [11], variants are weighted using data-adaptive
weights, reflecting the estimated effect of a variant on the
phenotype, and these weights can be potentially used to rank
variants. However, as explained above, for rare and low frequency
variants it is essential to make use of rich functional genomics
annotations. At the other extreme, one can rank variants based on
a functional score alone. This latter class of methods has the
important drawback, especially in the case of complex traits, that it
ignores case-control frequencies, and relies heavily on the accuracy
of the bioinformatics predictor. Based on simulation studies, we
have shown that hierarchical modeling that takes into account
both association evidence coming from the sequencing data, and
available functional genomics predictions, have better perfor-
mance compared with ranking based on a single bioinformatic
predictor alone (Text S3 and Figure S13).
We have focused here on the selection of variants that increase
risk to disease. However, one can in principle use the proposed
methods to identify protective variants. Instead of a Burden type
statistic, one can use a SKAT statistic in the backward elimination
procedure (also implemented in our software). Similarly, for the
hierarchical model, variants with low functional score and higher
frequency in controls compared with cases will be candidates for
protective variants.
Further improvements to the backward elimination procedure
are possible. For example, instead of partitioning variants into two
groups based on a binary bioinformatic predictor, such as non-
synonymous and synonymous, an alternative would be to calculate
stratified false discovery rates [63] or possibly covariate-modulated
local false discovery rates [64]. The advantage of such an
approach would be that more than one covariate can be added
to the backward-elimination procedure, although this point
Figure 4. Results from the backward elimination procedure for
non-synonymous and splice site variants in VPS13B. (a) The
change in p value is shown as variants are being removed one by one
(when the backward elimination procedure is run once on all non-
synonymous variants). (b) Distribution of return counts for non-
synonymous and splice site variants in VPS13B; overlaid is a fitted
mixture with two components.
doi:10.1371/journal.pgen.1004729.g004
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requires further work. Furthermore, information on the location of
a variant within a gene or region of interest, e.g. what functional
domain it affects, can be important, especially for missense
variants. We have previously described scan statistic approaches to
identify clusters of rare disease associated variants, and have
shown applications to both autism and schizophrenia studies
[65,66], suggesting that incorporating such location information
into the backward elimination procedure could improve the
identification of causal variants.
The estimates of a rare variant’s effect on disease from the
hierarchical model can have substantial bias. This happens
because in any particular gene or region only a small proportion
of variants are expected to be disease causing, and most of the
variants represent random genetic variation. Therefore, when
estimating odds ratios of causal variants, there is a strong shrinkage
effect toward the overall estimate. Incorporation of accurate
functional predictors in the hierarchical model is one possible way
to help attenuate this bias; further work is needed on finding better
ways to reduce the bias.
In addition to their ability to pinpoint likely causal variants, the
proposed methods can be used to prioritize variants for genotyping
in independent datasets for the purpose of replication or
validation. This is relevant when re-sequencing the gene or region
in additional datasets is too expensive, and one chooses instead to
genotype variants discovered in the original study [67]. Moreover,
the proposed approaches can be used at a genome-wide scale, by
first selecting the promising genes based on the overall gene-based
test or other criteria (e.g. good biological candidate) followed by
the backward elimination and hierarchical model approach to
prioritize the variants within the genes identified as promising.
Such a genome-wide analysis can, for example, identify classes of
functional elements or domains enriched among the top variants
in the selected genes.
The proposed methods are applicable to case-control or
population-based designs. However, family-based designs repre-
sent a natural way to identify causal variants. For example, in
multiplex families, significant sharing of a non-synonymous
mutation among multiple affected relatives can be an important
indication of causality. Bayesian approaches in this context have
been developed before [68], and further work in this area is worth
pursuing.
In summary, we have proposed and investigated two comple-
mentary statistical methods to identify causal variants among the
naturally occurring genetic variation at a locus. They are able to
incorporate sequencing data with various functional predictors on
variants, and select a small number of variants that are enriched in
causal variants. In the current study, we applied the proposed
methods to a gene known to contain risk variants for ASD as
proof-of-principle, and identify several interesting variants,
including two LoF variants and a homozygous probably damaging
variant likely important to autism risk.
Supporting Information
S1 Figure The effect of removing causal vs. non-causal variants
on the p value for the reduced set (Step 2 of the backward
elimination procedure). Results are shown for one (typical)
simulated dataset with 2000 individuals, in a 25 kb region with
10% causal variants, under model M2. Removing the non-causal
variant corresponding to the red circle leads to the largest drop in
p value for the reduced set, and hence this variant is being
removed in this iteration from the current set (Step 3 of the
backward elimination procedure).
(EPS)
S2 Figure Non-parametric mixture fit to sample distribution of
return counts in the backward elimination procedure (simulated
example). The return counts are for non-synonymous variants,
and two groups can be distinguished, one corresponding to the
‘‘non-interesting’’ class, and the other to the ‘‘interesting’’ class.
(EPS)
S3 Figure (a) Median rank of causal variants among the non-
synonymous variants for two disease models (M1 and M2) and
three values for the NS:S ratio (R= {0.6, 1.0, 1.4}). The
proportion of causal variants in the region is 10%. HM refers
to the original hierarchical model with ranking of the causal
variants among the non-synonymous variants, based on their
estimated effects, BE refers to the backward elimination
procedure for non-synonymous variants, and HMS refers to the
ranking of causal variants only among those non-synonymous
variants selected by the backward elimination procedure, with
ranks based on the estimated effects from the hierarchical model.
(b) The number of causal variants in Top 10 for non-synonymous
variants.
(EPS)
S4 Figure (a) Median rank of causal variants among the
synonymous variants for two disease models (M1 and M2) and
three values for the NS:S ratio (R= {0.6, 1.0, 1.4}). The
proportion of causal variants in the region is 20%. HM refers to
the original hierarchical model with ranking of the causal variants
among the synonymous variants, based on their estimated effects,
BE refers to the backward elimination procedure for synonymous
variants, and HMS refers to the ranking of causal variants only
among those synonymous variants selected by the backward
elimination procedure, with ranks based on the estimated effects
from the hierarchical model. (b) The number of causal variants in
Top 10 for synonymous variants.
(EPS)
S5 Figure (a) Median rank of causal variants among the
synonymous variants for two disease models (M1 and M2) and
three values for the NS:S ratio (R= {0.6, 1.0, 1.4}). The
proportion of causal variants in the region is 10%. HM refers to
the original hierarchical model with ranking of the causal variants
among the synonymous variants, based on their estimated effects,
BE refers to the backward elimination procedure for synonymous
variants, and HMS refers to the ranking of causal variants only
among those synonymous variants selected by the backward
elimination procedure, with ranks based on the estimated effects
from the hierarchical model. (b) The number of causal variants in
Top 10 for synonymous variants.
(EPS)
S6 Figure The effect of multiple bioinformatic predictors for
non-synonymous variants. Ranking is done only within the set of
variants selected by the backward elimination procedure. (a)
Median rank of causal variants for two disease models (M1 and
M2) and three values for the NS:S ratio (R= {0.6, 1.0, 1.4}). The
proportion of causal variants in the region is 10%. HMS refers to
the hierarchical model with ranking of the causal variants among
the selected non-synonymous variants, based on their estimated
effects, B1 refers to the hierarchical model with one bioinformatic
predictor (B1, Table 2), B2 refers to the hierarchical model with
one bioinformatic predictor (B2), mB1 refers to the hierarchical
model with three bioinformatic predictors (B1, B1, and B2), and
mB2 refers to the hierarchical model with four bioinformatic
predictors (four B1). (b) The number of causal variants in Top 10
for non-synonymous variants.
(EPS)
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S7 Figure The effect of incorporating bioinformatic predictors (B1
and B2) for non-synonymous variants in the backward elimination
procedure (BE1 and BE2), and in the hierarchical model (B1 and B2)
on the number of causal variants in Top 10. Ranking is done only
within the set of variants selected by the backward elimination
procedure. Results for two disease models (M1 and M2) and three
values for the NS:S ratio (R={0.6, 1.0, 1.4}) are shown. mB refers to
the hierarchical model with three bioinformatic predictors (B1, B1,
and B2). (a) 20% causal. (b) 10% causal.
(EPS)
S8 Figure Distribution of return counts from the backward
elimination procedure applied to synonymous variants in
VPS13B; overlaid is a fitted mixture with two components.
(EPS)
S9 Figure Molecular validation and transmission pattern analysis
for two cases with the c.9592C.T (p.Arg3198Trp) variant (A, B), the
c.2650+2T.G singleton LoF (C) and the c.10148C.G (p.Ser3383-
Ter) singleton missense (D). For each family, the electropherogram of
the relevant region is shown below the corresponding individual.
(EPS)
S10 Figure Schematic representation of VPS13B (Q7Z768-2) in the
Golgi membrane and the variants identified in this study. The Chorein
N-terminal domain is shown inmagenta, DUF1162 in cyan, and ATG
C-terminal domain in green. The Golgi targeting domain overlaps
with the ATG C and is shown in purple. Amino acids affected by LoF
are shown in black, probably damaging missense in red, possibly
damaging in yellow, and benign in grey. The arrow points to the
homozygous probably damaging variant (p.Arg3198Trp).
(EPS)
S11 Figure The effect of incorporating a random bioinformatic
predictor R for non-synonymous variants in the hierarchical model
(20% causal). Ranking is done only within the set of variants selected
by the backward elimination procedure. Results for two disease
models (M1 and M2) and three values for the NS:S ratio (R={0.6,
1.0, 1.4}) are shown. RB1 refers to the hierarchical model with two
bioinformatic predictors (a random one, i.e. R, and B1). (a) Median
rank of causal variants among the non-synonymous variants. (b) The
number of causal variants in Top 10 for non-synonymous variants.
(EPS)
S12 Figure The effect of incorporating a random bioinformatic
predictor R for non-synonymous variants in the hierarchical
model (10% causal). Ranking is done only within the set of variants
selected by the backward elimination procedure. Results for two
disease models (M1 and M2) and three values for the NS:S ratio
(R= {0.6, 1.0, 1.4}) are shown. RB1 refers to the hierarchical
model with two bioinformatic predictors (a random one, i.e. R,
and B1). (a) Median rank of causal variants among the non-
synonymous variants. (b) The number of causal variants in Top 10
for non-synonymous variants.
(EPS)
S13 Figure ROC curves of the z-values estimated from a
hierarchical model including PolyPhen-2 scores and an indicator
for the non-synonymous vs. synonymous status as the higher level
covariates (solid curves), and ROC curves based on ranking
variants using the PolyPhen-2 scores alone (dashed curves); 10% of
variants are assumed truly causal variants; associations between
the PolyPhen-2 scores and the causal status vary from odds ratio of
2 (blue) to 4 (red); m, the effect size as a function of standard
deviations, is assumed to be 0.5; estimates are averaged across 400
simulations (see Text S3 for more details on the simulation setup).
(EPS)
S1 Table Absolute biases and coverage probabilities when
estimating variant effects in the hierarchical model, for the
simulation scenarios in Table 2. Results for two disease models
(M1 and M2 - Table 1) are shown. Several functional predictors
are used in the hierarchical model: non-synonymous vs.
synonymous (NS vs. S), B1, B2, and a scenario with three
functional, independent predictors: two B1’s and one B2.
(PDF)
S2 Table Top 20 functional (non-synonymous, nonsense and
splice-site) variants in VPS13B; only a functional vs. synonymous
indicator is used as a binary functional predictor. The variants are
sorted according to return count. nA (nU ) is the minor allele count
in cases (controls); hom_A (hom_U) is the number of homozygous
genotypes in cases (controls); RC is the return count from the
backward elimination procedure; log odds ratios and their
standard errors are estimated from the hierarchical model. SnpEff
predicted effects are also reported. PolyPhen-2 and GERP_RS
scores are also reported but they are not used in the backward
elimination procedure.
(PDF)
S1 Text Describes details about the Autism Sequencing Dataset.
(PDF)
S2 Text Describes details about the nonparametric estimation of
multivariate mixtures.
(PDF)
S3 Text Presents comparisons between variant ranking from
hierarchical model and variant ranking from PolyPhen-2 scores.
(PDF)
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